Xiaflex: the enzyme that eats the plaque

What it is

The generic name is collagenase clostridium histolyticum, usually shortened to CCH. It is a blend of two collagenases harvested from Clostridium histolyticum, a bacterium whose enzymes evolved to break down connective tissue. Purified and injected in a tiny volume straight into the plaque, the two enzymes cut collagen strands at different points along their length, so that the dense, rope-like scar loses its structure and can be pulled apart mechanically.

That last part matters. Xiaflex does not dissolve a plaque into nothing. It weakens it, and then the urologist, and later you, physically stretch the weakened tissue to straighten the shaft. The drug and the modeling are one treatment, not two, and the trials that got it approved tested them together.

What the trials actually delivered

Approval rested on two identical placebo-controlled trials called IMPRESS I and II, published in 2013: 832 men with stable Peyronie's disease and a curve of 30° to 90°, randomized to collagenase or placebo, both arms modeled the same way. The primary result is the number to carry around:

Read that honestly. A man who walks in at 60° and gets an average result walks out at around 40°. That is a different penis to live with, and for many men it is the difference between sex that works and sex that doesn't. It is not a straight line, and a urologist who promises one is selling. Larger curves tend to shed more degrees in absolute terms; the response is also uneven, with a meaningful minority improving very little.

The gains appear to hold. Follow-up of trial participants out to several years found the improvement was maintained without further treatment, and the American Urological Association guideline lists intralesional collagenase with modeling as the recommended injectable for stable disease in the 30° to 90° range. Verapamil and interferon, the older in-office injections, carry weaker recommendations on thinner evidence.

What a course looks like

The label protocol, the one the trials used, runs like this. Your urologist may compress it, and increasingly does, but this is the reference version:

1. One cycle is two injections of 0.58 mg, given one to three days apart, into the plaque at the point of maximum curvature. Injection needs a certified prescriber; more on that below.
2. One to three days after the second injection, the urologist performs in-office modeling: a gentle, held stretch of the flaccid penis against the curve. It is uncomfortable rather than agonizing, and it is over in a minute or two.
3. Home modeling follows, three times a day for six weeks, taught in the office. This is the part that rewards discipline.
4. Cycles repeat about six weeks apart, up to four cycles, so up to eight injections over roughly six months. Men who reach a curve under 15° can stop early.

Two things have shifted since 2013. Shortened protocols (for example three injections at four-week intervals, one per visit) have reported results comparable to the eight-injection course with far fewer appointments, and many centers use a variation of them. And traction devices worn between cycles, which turn the six-week gap into a continuous mechanical pull, have shown added curvature and length gains in prospective studies. Ask which protocol your urologist uses and why; the answer tells you how current their practice is.

Doses and schedules here are the manufacturer's label and the published protocols, given as literacy so you can follow the plan you are handed. Selecting the protocol, the injection site, and when to stop is the injecting urologist's call.

Who it is for, and who it is not

The candidate the evidence describes is specific, and it is worth checking yourself against it before the consultation so the conversation starts in the right place:

• Stable disease. The curve has stopped changing and the pain has settled, usually at least a year in. Injecting an active plaque is treating a moving target, and the phase logic from the Peyronie's primer applies in full.
• A curve of 30° to 90°. Under 30° rarely justifies the risk; over 90° was not studied and usually points toward surgery.
• Dorsal or lateral curvature. Upward or sideways. Ventral (downward) curves were excluded from the trials because the urethra runs along the underside, and the label warns against injecting near it.
• A palpable, non-calcified plaque. Calcified plaques, the kind that show up as bone-white on ultrasound, do not respond; the enzyme has nothing soft to cut.
• Erections that work. Trial entry required erectile function adequate for sex, with or without a PDE5 inhibitor. If erections have already failed, straightening a shaft that no longer fills solves the wrong problem, and the conversation turns toward an implant, which straightens as a side effect.

An hourglass deformity or indentation without a curve is also outside the label. Some urologists treat combined deformities off-label; that is a judgment call to have out loud, not a reason to shop for a yes.

The risks, and the one that gets its own program

Expect to be bruised. In the trials, penile bruising or hematoma, swelling, and pain at the injection site affected the large majority of treated men, and a swollen, purple shaft for a week or two after each cycle is normal rather than a complication. Itching, blood blisters, and small skin splits happen less often. Nearly all of it resolves on its own.

The serious one is corporal rupture: a tear of the tunica, the same sheath the plaque sits in, which the enzyme has just weakened. In the trials it occurred in about 1 in 200 collagenase-treated men, along with a handful of hematomas severe enough to need intervention. A rupture presents as a sudden pop, sharp pain, and rapid swelling, typically during an erection or sex, and it needs surgical repair, promptly. That is why the manufacturer's label has an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) for the Peyronie's indication: only urologists who have completed the certification can prescribe and inject it, and the drug ships only to certified sites. If someone offering it is not a urologist, that is your answer.

The other consequence is the sex embargo. No sexual activity, including masturbation, for at least four weeks after the second injection of each cycle, and not until pain and swelling have gone. Across a full course that adds up to a lot of the year, and it is the single most common reason men underestimate what they are signing up for. Plan for it, and tell a partner, because a rupture from sex at week two is the avoidable version of the worst outcome.

Rarer still: allergic reactions, including anaphylaxis, have been reported, which is part of why injections happen in an office and not at home. Xiaflex is never a self-administered drug, and there is no legitimate channel for obtaining a vial outside a certified clinic.

The cost question

Each injection is a single-use vial, and vials are expensive: list prices run in the low thousands of dollars apiece, so a full eight-injection course reaches well into five figures before the office visits. Most US insurers, including Medicare, cover it for Peyronie's when the candidacy criteria above are documented, which is one more reason the criteria are worth knowing. Prior authorization is the norm; a shortened protocol reduces the bill roughly in proportion to the vials it saves. Our cost primer covers how to get a real number before the first appointment.

The same vial, in the hand

Xiaflex was approved for Peyronie's three years after its first indication, Dupuytren's contracture, the fibrous cord in the palm that curls a finger toward it. The two conditions are cousins: the same disordered collagen deposition, a shared genetic tendency, and an overlap in about a fifth of men with Peyronie's. In the hand, a single injection into the cord followed by a straightening manipulation a day or two later releases most treated joints, and the drug is now a standard alternative to open surgery there, with recurrence over the following years as its main limitation.

If you have a bent finger and a bent penis, say so at the consultation. It changes nothing about the injection, but it confirms the diagnosis, it may explain a family history, and it means the urologist and the hand surgeon are treating one disease from two ends.

The bottom line

Xiaflex is a real drug for a condition that had none: an enzyme that weakens the plaque so that modeling can straighten it, backed by two placebo-controlled trials, a guideline recommendation, and years of follow-up. Expect a partial correction, on the order of a third of the curve, over roughly six months of cycles and sex embargoes, with a small but genuine rupture risk that is why only certified urologists give it. It fits a specific man: stable disease, 30° to 90°, not ventral, not calcified, erections intact. If that is you, it belongs at the top of the non-surgical list. If it is not, the honest answer is a different treatment, and a good urologist will say so.

Common questions